nach oben

Current Diabetes Reports

Erschienen in:

01.09.2015 | Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis

verfasst von: Daniel Li, Jennifer Kirsop, W. H. Wilson Tang

Erschienen in: Current Diabetes Reports | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

What we understand about diabetes from decades of genetics research is now being supplemented with exciting new evidence based on a better understanding of how one of the biggest “environmental” factors the body is exposed to is influencing the pathogenesis of disease. The recent discovery that certain dietary nutrients possessing a trimethylamine (TMA) moiety (namely choline/phosphatidylcholine and L-carnitine) participate in the development of atherosclerotic heart disease has renewed attention towards the contributions of gut microbiota in the development of cardiovascular diseases. Collectively, animal and human studies reveal that conversion of these nutrient precursors to trimethylamine N-oxide (TMAO) depends on both microbial composition and host factors, and can be induced by dietary exposures. In addition, circulating TMAO levels are strongly linked to cardiovascular disease risks and various adverse cardio-renal consequences. Our group and others have further demonstrated that circulating TMAO levels are elevated in patients with type 2 diabetes mellitus compared to healthy controls and gut microbiota-dependent phosphatidylcholine metabolism has been implicated in metabolic dysregulation and insulin resistance in animal models. Therefore, preventive strategies to minimize adverse consequences associated with TMAO generation in the diabetic population are warranted.

Eckburg PB et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–8.PubMedCentralCrossRefPubMed

Claesson MJ et al. Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One. 2009;4(8):e6669.PubMedCentralCrossRefPubMed

Turnbaugh PJ et al. The human microbiome project. Nature. 2007;449(7164):804–10.PubMedCentralCrossRefPubMed

Backhed F et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.PubMedCentralCrossRefPubMed

Backhed F et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979–84.PubMedCentralCrossRefPubMed

Turnbaugh PJ et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.CrossRefPubMed

Amar J et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia. 2011;54(12):3055–61.CrossRefPubMed

Moreno-Navarrete JM et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond). 2012;36(11):1442–9.CrossRef

Cani PD et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72.CrossRefPubMed

10.

Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81(3):1031–64.PubMed

11.

Cummings JH et al. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr. 1979;32(10):2094–101.PubMed

12.

Goncalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate transport. Curr Drug Metab. 2013;14(9):994–1008.CrossRefPubMed

13.

Cook SI, Sellin JH. Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther. 1998;12(6):499–507.CrossRefPubMed

14.

Pouteau E et al. Acetate, propionate and butyrate in plasma: determination of the concentration and isotopic enrichment by gas chromatography/mass spectrometry with positive chemical ionization. J Mass Spectrom. 2001;36(7):798–805.CrossRefPubMed

15.

Ray TK et al. Long-term effects of dietary fiber on glucose tolerance and gastric emptying in noninsulin-dependent diabetic patients. Am J Clin Nutr. 1983;37(3):376–81.PubMed

16.

Mendeloff AI. Dietary fiber and human health. N Engl J Med. 1977;297(15):811–4.CrossRefPubMed

17.

Robertson MD et al. Prior short-term consumption of resistant starch enhances postprandial insulin sensitivity in healthy subjects. Diabetologia. 2003;46(5):659–65.PubMed

18.••

Karlsson FH et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498(7452):99–103. These two studies (18,19) provide the first metagenomic evidence of differing profiles between diabetes and normal individuals and suggest the potential to predict development of disease from metagenomic sequences.

19.••

Qin J et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. These two studies (18,19) provide the first metagenomic evidence of differing profiles between diabetes and normal individuals and suggest the potential to predict development of disease from metagenomic sequences. CrossRefPubMed

20.

Le Poul E et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003;278(28):25481–9.CrossRefPubMed

21.

Brown AJ et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278(13):11312–9.CrossRefPubMed

22.

Kimura I et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4:1829.PubMedCentralCrossRefPubMed

23.

Samuel BS et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A. 2008;105(43):16767–72.PubMedCentralCrossRefPubMed

24.

Tolhurst G et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012;61(2):364–71.PubMedCentralCrossRefPubMed

25.

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–39.CrossRefPubMed

26.

Freeland KR, Wolever TM. Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br J Nutr. 2010;103(3):460–6.CrossRefPubMed

27.

Vrieze A et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6. e7.CrossRefPubMed

28.

Amar J et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008;87(5):1219–23.PubMed

29.

Shi H et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116(11):3015–25.PubMedCentralCrossRefPubMed

30.

Saemann MD et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J. 2000;14(15):2380–2.PubMed

31.

Roelofsen H, Priebe MG, Vonk RJ. The interaction of short-chain fatty acids with adipose tissue: relevance for prevention of type 2 diabetes. Benefic Microbes. 2010;1(4):433–7.CrossRef

32.

Peng L et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619–25.PubMedCentralCrossRefPubMed

33.•

Koeth RA et al. gamma-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20(5):799–812. This study and reference [47] provide novel insights into the metabolism of TMAO and its associations with various gut microbiome profiles. CrossRefPubMed

34.

Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204–11.PubMedCentralCrossRefPubMed

35.

Gregory JC et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2014;290:5647–60.CrossRefPubMed

36.•

Wang Z et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. In this study, Wang et al. uses a metabolomic screen to identify TMAO as a novel gut microbiota-dependent metabolite that is a potential modifiable risk factor for cardiovascular disease. PubMedCentralCrossRefPubMed

37.

Tang WH et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64(18):1908–14.CrossRefPubMed

38.•

Tang WH et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–84. In this clinical study with over 4000 participants, the authors reconfirmed the gut microbiota dependence of TMAO in human subjects and found that serum TMAO levels predicted 3-year incident cardiovascular risk in a dose-dependent manner. PubMedCentralCrossRefPubMed

39.

Tang WH et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2014;21:91–6.CrossRefPubMed

40.

Wang Z et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J. 2014;35(14):904–10.PubMedCentralCrossRefPubMed

41.

Wang TJ et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53.PubMedCentralCrossRefPubMed

42.

Lever M et al. Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study. PLoS ONE. 2014;9(12), e114969.PubMedCentralCrossRefPubMed

43.

Gao X et al. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. 2014;118(4):476–81.CrossRefPubMed

44.••

Miao J et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun. 2015;6:6498. This study shows that knockdown of FMO3 and subsequently TMAO levels can prevent the development of hyperglycemia, hyperlipidemia, and atherosclerosis in a diabetes mouse model. PubMedCentralCrossRefPubMed

45.

Shih DM et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res. 2015;56(1):22–37.CrossRefPubMed

46.

Tang WH et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–55.CrossRefPubMed

47.•

Koeth RA et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85. See reference 33. PubMedCentralCrossRefPubMed

48.

Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;67(11):615–23.PubMedCentralCrossRefPubMed

49.

Chu DM et al. Choline and betaine food sources and intakes in Taiwanese. Asia Pac J Clin Nutr. 2012;21(4):547–57.PubMed

50.

Li Z, Vance DE. Phosphatidylcholine and choline homeostasis. J Lipid Res. 2008;49(6):1187–94.CrossRefPubMed

51.

Paoletti L et al. Role of phosphatidylcholine during neuronal differentiation. IUBMB Life. 2011;63(9):714–20.PubMed

52.

Lever M, Slow S. The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem. 2010;43(9):732–44.CrossRefPubMed

53.

Lever M et al. Variability of plasma and urine betaine in diabetes mellitus and its relationship to methionine load test responses: an observational study. Cardiovasc Diabetol. 2012;11:34.PubMedCentralCrossRefPubMed

54.

Lever M et al. Betaine and secondary events in an acute coronary syndrome cohort. PLoS One. 2012;7(5), e37883.PubMedCentralCrossRefPubMed

55.

Wijekoon EP, Brosnan ME, Brosnan JT. Homocysteine metabolism in diabetes. Biochem Soc Trans. 2007;35(Pt 5):1175–9.CrossRefPubMed

56.

Konstantinova SV et al. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr. 2008;138(5):914–20.PubMed

57.

Schartum-Hansen H et al. Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients. PLoS One. 2013;8(8), e69454.PubMedCentralCrossRefPubMed

58.

Lever M et al. Plasma lipids and betaine are related in an acute coronary syndrome cohort. PLoS One. 2011;6(7), e21666.PubMedCentralCrossRefPubMed

59.

Rajaie S, Esmaillzadeh A. Dietary choline and betaine intakes and risk of cardiovascular diseases: review of epidemiological evidence. ARYA Atheroscler. 2011;7(2):78–86.PubMedCentralPubMed

60.

Danne O et al. Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. Clin Chim Acta. 2007;383(1–2):103–9.CrossRefPubMed

61.

Danne O et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol. 2003;91(9):1060–7.CrossRefPubMed

62.

LeLeiko RM et al. Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol. 2009;104(5):638–43.CrossRefPubMed

63.

Bidulescu A et al. Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. BMC Cardiovasc Disord. 2007;7:20.PubMedCentralCrossRefPubMed

64.

Bidulescu A et al. Repeatability and measurement error in the assessment of choline and betaine dietary intake: the Atherosclerosis Risk in Communities (ARIC) study. Nutr J. 2009;8:14.PubMedCentralCrossRefPubMed

65.

Dumas ME et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006;103(33):12511–6.PubMedCentralCrossRefPubMed

66.

Mingrone G. Carnitine in type 2 diabetes. Ann N Y Acad Sci. 2004;1033:99–107.CrossRefPubMed

67.

Capaldo B et al. Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1991;14(3):191–5.CrossRefPubMed

68.

Ferrannini E et al. Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol. 1988;255(6 Pt 1):E946–52.PubMed

69.

Mynatt RL. Carnitine and type 2 diabetes. Diabetes Metab Res Rev. 2009;25 Suppl 1:S45–9.CrossRefPubMed

70.

Vidal-Casariego A et al. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes. 2013;121(4):234–8.CrossRefPubMed

71.

DiNicolantonio JJ et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88(6):544–51.CrossRefPubMed

72.

Shang R, Sun Z, Li H. Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2014;14:88.PubMedCentralCrossRefPubMed

73.

Craciun S, Balskus EP. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A. 2012;109(52):21307–12.PubMedCentralCrossRefPubMed

74.

Zhu Y et al. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc Natl Acad Sci U S A. 2014;111(11):4268–73.PubMedCentralCrossRefPubMed

75.

Qin J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59–65.PubMedCentralCrossRefPubMed

76.

Turnbaugh PJ et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–4.PubMedCentralCrossRefPubMed

77.

Furet JP et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59(12):3049–57.PubMedCentralCrossRefPubMed

78.

Zhang X et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013;8(8), e71108.PubMedCentralCrossRefPubMed

79.

Remely M et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene. 2014;537(1):85–92.CrossRefPubMed

80.

Karlsson CL et al. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring). 2012;20(11):2257–61.CrossRef

81.

Everard A et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes. 2011;60(11):2775–86.PubMedCentralCrossRefPubMed

82.

Everard A et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066–71.PubMedCentralCrossRefPubMed

83.

Shin NR et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63(5):727–35.CrossRefPubMed

84.

Walker AW et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;5(2):220–30.PubMedCentralCrossRefPubMed

85.

Wu GD et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.PubMedCentralCrossRefPubMed

86.

David LA et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.PubMedCentralCrossRefPubMed

87.

Lozupone CA et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220–30.PubMedCentralCrossRefPubMed

Titel: Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis
verfasst von: Daniel Li
Jennifer Kirsop
W. H. Wilson Tang
Publikationsdatum: 01.09.2015
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 9/2015
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-015-0634-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2015

Update on Estimation of Kidney Function in Diabetic Kidney Disease

Infant Feeding and Timing of Complementary Foods in the Development of Type 1 Diabetes

From Individuals to International Policy: Achievements and Ongoing Needs in Diabetes Advocacy

Salt Restriction in Diabetes

Impact of Lifestyle Modification on Diabetic Kidney Disease